Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
For the quarter ended December 2024, Nektar Therapeutics (NKTR) reported revenue of $29.18 million, up 22.1% over the same period last year. EPS came in at $0.15, compared to -$0.22 in the year ...
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned a consensus rating of “Buy” from the six analysts ...
(RTTNews) - Below are the earnings highlights for Nektar Therapeutics (NKTR): Earnings ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
Hosted on MSN3d
Nektar Therapeutics Q4 2024 Earnings PreviewNektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q4 earnings results on Wednesday, March 12th, after market close. The consensus EPS Estimate is -$0.20 (+9.1% Y/Y) and the consensus Revenue ...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...
Nektar Therapeutics (NKTR) reported $29.18 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 22.1%. EPS of -$0.15 for the same period compares to -$ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results